PH12014501365B1 - Compounds - Google Patents
Compounds Download PDFInfo
- Publication number
- PH12014501365B1 PH12014501365B1 PH12014501365A PH12014501365A PH12014501365B1 PH 12014501365 B1 PH12014501365 B1 PH 12014501365B1 PH 12014501365 A PH12014501365 A PH 12014501365A PH 12014501365 A PH12014501365 A PH 12014501365A PH 12014501365 B1 PH12014501365 B1 PH 12014501365B1
- Authority
- PH
- Philippines
- Prior art keywords
- phenyl
- chloro
- imidazol
- tetrazol
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1122139.7A GB2497806A (en) | 2011-12-21 | 2011-12-21 | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors |
| GB201217290A GB201217290D0 (en) | 2012-09-27 | 2012-09-27 | Compounds |
| PCT/GB2012/053217 WO2013093484A1 (en) | 2011-12-21 | 2012-12-20 | Pyridinone and pyrimidinone derivatives as factor xia inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12014501365A1 PH12014501365A1 (en) | 2014-09-22 |
| PH12014501365B1 true PH12014501365B1 (en) | 2014-09-22 |
Family
ID=47553259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12014501365A PH12014501365B1 (en) | 2011-12-21 | 2014-06-16 | Compounds |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9732085B2 (OSRAM) |
| EP (2) | EP2794597B1 (OSRAM) |
| JP (2) | JP6137193B2 (OSRAM) |
| KR (1) | KR102011534B1 (OSRAM) |
| CN (1) | CN104136431B (OSRAM) |
| AU (1) | AU2012356374B2 (OSRAM) |
| BR (1) | BR112014015669B1 (OSRAM) |
| CA (1) | CA2859604C (OSRAM) |
| DK (1) | DK2794597T3 (OSRAM) |
| ES (2) | ES2655669T3 (OSRAM) |
| HU (1) | HUE036010T2 (OSRAM) |
| IL (1) | IL233154A (OSRAM) |
| IN (1) | IN2014CN04676A (OSRAM) |
| MX (1) | MX351471B (OSRAM) |
| NO (1) | NO2794597T3 (OSRAM) |
| PH (1) | PH12014501365B1 (OSRAM) |
| PL (1) | PL2794597T3 (OSRAM) |
| PT (1) | PT2794597T (OSRAM) |
| RU (1) | RU2630677C2 (OSRAM) |
| SG (1) | SG11201403402VA (OSRAM) |
| TW (1) | TWI613199B (OSRAM) |
| WO (1) | WO2013093484A1 (OSRAM) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5844287B2 (ja) | 2010-02-11 | 2016-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としてのマクロ環 |
| ES2562903T3 (es) * | 2011-07-13 | 2016-03-09 | Santen Pharmaceutical Co., Ltd | Nuevo compuesto que tiene actividad inhibidora de PARP |
| EP2899183B1 (en) | 2011-10-14 | 2018-09-19 | Bristol-Myers Squibb Company | Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors |
| US9000172B2 (en) | 2011-10-14 | 2015-04-07 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
| CN103987696B (zh) | 2011-10-14 | 2016-12-21 | 百时美施贵宝公司 | 作为因子xia抑制剂的取代的四氢异喹啉化合物 |
| NO2794597T3 (OSRAM) * | 2011-12-21 | 2018-04-14 | ||
| TW201332988A (zh) * | 2011-12-23 | 2013-08-16 | Millennium Pharm Inc | 雜芳基化合物及其用途 |
| CN104640843A (zh) | 2012-07-19 | 2015-05-20 | 大日本住友制药株式会社 | 1-(环烷基羰基)脯氨酸衍生物 |
| HRP20170506T1 (hr) | 2012-08-03 | 2017-06-02 | Bristol-Myers Squibb Company | Dihidropiridon p1 kao inhibitori xia faktora |
| TW201410666A (zh) | 2012-08-03 | 2014-03-16 | 必治妥美雅史谷比公司 | 二氫吡啶酮ｐ１作爲凝血因子ｘｉａ抑制劑 |
| EP2906541B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2014059202A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| BR112015007937A2 (pt) | 2012-10-12 | 2017-07-04 | Bristol Myers Squibb Co | formas cristalinas de um inibidor de fator xia |
| EP2978751B1 (en) | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
| WO2014160592A2 (en) * | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| JP6410819B2 (ja) * | 2013-07-23 | 2018-10-24 | バイエル ファーマ アクチエンゲゼルシャフト | 置換オキソピリジン誘導体および第ＸＩａ因子／血漿としてのその使用 |
| CN105849109B (zh) * | 2013-10-30 | 2018-01-23 | 拜耳制药股份公司 | 取代的氧代吡啶衍生物 |
| WO2015116886A1 (en) * | 2014-01-31 | 2015-08-06 | Bristol-Myers Squibb Company | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| NO2760821T3 (OSRAM) | 2014-01-31 | 2018-03-10 | ||
| US9676723B2 (en) | 2014-02-11 | 2017-06-13 | Merck Sharp & Dohme Corp | Factor XIa inhibitors |
| US9944643B2 (en) | 2014-02-11 | 2018-04-17 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| CN105829298B (zh) * | 2014-02-14 | 2019-02-01 | 四川海思科制药有限公司 | 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用 |
| EP3134408B1 (en) | 2014-04-22 | 2020-08-12 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| WO2016011940A1 (zh) * | 2014-07-25 | 2016-01-28 | 江苏恒瑞医药股份有限公司 | 氮茚-酰胺类衍生物、其制备方法及其在医药上的应用 |
| WO2016015593A1 (en) | 2014-07-28 | 2016-02-04 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| JP6526796B2 (ja) | 2014-09-04 | 2019-06-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｆｘｉａ阻害剤であるジアミドマクロ環 |
| CN104311537B (zh) * | 2014-09-19 | 2016-08-24 | 广东东阳光药业有限公司 | 含有嘧啶酮乙酰基取代基吡唑类化合物及其组合物及用途 |
| ES2713624T3 (es) * | 2014-09-24 | 2019-05-23 | Bayer Pharma AG | Derivados de oxopiridina sustituidos |
| ES2722423T3 (es) * | 2014-09-24 | 2019-08-12 | Bayer Pharma AG | Derivados de oxopiridina sustituidos |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| NO2721243T3 (OSRAM) * | 2014-10-01 | 2018-10-20 | ||
| AU2015362422B2 (en) * | 2014-12-10 | 2019-11-14 | Ono Pharmaceutical Co., Ltd. | Dihydroindolizinone derivative |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| RU2649141C2 (ru) * | 2015-04-20 | 2018-03-30 | государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) | 3,4-диметил-6-(3-пиридил)-N-фенил-2-оксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий противогрибковое действие в отношении штамма Candida albicans |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| JO3703B1 (ar) * | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| RU2653511C2 (ru) * | 2015-07-29 | 2018-05-10 | государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) | 4-метил-n-2,4-диметилфенил-6-(3-фторфенил)-2-тиоксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий анальгетическое действие |
| US10336730B2 (en) | 2015-08-05 | 2019-07-02 | Bristol-Myers Squibb Company | Substituted glycine derived FXIA inhibitors |
| CN106496249B (zh) * | 2015-09-07 | 2019-12-13 | 江苏恒瑞医药股份有限公司 | 噁唑并吲哚类衍生物、其制备方法及其在医药上的应用 |
| US10344039B2 (en) * | 2015-10-29 | 2019-07-09 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use |
| CA2998902C (en) | 2015-10-29 | 2024-03-26 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as factor xia inhibitors |
| JP6992284B2 (ja) * | 2016-06-06 | 2022-01-13 | 小野薬品工業株式会社 | ジヒドロインドリジノン誘導体を含有する医薬組成物 |
| TW201808908A (zh) | 2016-08-22 | 2018-03-16 | 美商默沙東藥廠 | 因子XIa抑制劑 |
| CN113912586B (zh) | 2016-08-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
| WO2018065330A1 (de) | 2016-10-07 | 2018-04-12 | Mitsubishi Hitec Paper Europe Gmbh | Wärmeempfindliches aufzeichnungsmaterial |
| EP3305538A1 (de) | 2016-10-07 | 2018-04-11 | Mitsubishi HiTec Paper Europe GmbH | Wärmeempfindliches aufzeichnungsmaterial |
| CN106950319B (zh) * | 2017-04-20 | 2019-08-30 | 西安科技大学 | 一种检测特鲁曲班光学异构体含量的方法 |
| CN109507345B (zh) * | 2017-09-15 | 2022-08-05 | 万特制药(海南)有限公司 | 重酒石酸卡巴拉汀中间体及其杂质的分离测定方法 |
| UA126251C2 (uk) * | 2018-02-27 | 2022-09-07 | Джянгсу Хенгруй Медісін Ко., Лтд. | Кристалічна форма похідної оксопіколінаміду та спосіб її отримання |
| EP3822264A4 (en) | 2018-07-02 | 2021-11-10 | Jiangsu Hengrui Medicine Co., Ltd. | CRYSTALLINE FORMS OF AN OXYPYRIDINE AMIDE DERIVATIVE AND THEIR PREPARATION PROCESS |
| TWI825144B (zh) * | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | 第二型轉麩醯胺酸酶(tg2)抑制劑 |
| CN111727186B (zh) * | 2018-11-11 | 2022-11-08 | 上海海雁医药科技有限公司 | 双杂环取代的吡啶-2(1h)-酮衍生物、其制法与医药上的用途 |
| SG11202105697SA (en) * | 2018-11-30 | 2021-06-29 | Ono Pharmaceutical Co | Novel crystal of (3s)-3-[2-(6-amino-2-fluoropyridine-3-yl)-4-fluoro-1h-imidazole-5-yl]-7-[5-chloro-2-(1h-tetrazole-1-yl)phenyl]-2,3-dihydroindolizine-5(1h)-one |
| CN109836360B (zh) * | 2019-03-19 | 2021-08-13 | 南京恩泰医药科技有限公司 | 一种甲苯磺酸依度沙班中间体的制备方法及中间体化合物 |
| CN112028877B (zh) * | 2019-06-04 | 2021-11-26 | 江西济民可信集团有限公司 | 烷氧吡啶酮化合物及其制备方法和用途 |
| AU2020301451B2 (en) * | 2019-06-28 | 2023-02-16 | Jiangxi Jemincare Group Co., Ltd | Tricyclic compound, preparation method therefor and use thereof |
| KR20220084301A (ko) * | 2019-09-27 | 2022-06-21 | 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 | FXIa 억제제와 이의 제조 방법 및 의약 용도 |
| CN112778277B (zh) * | 2019-11-11 | 2024-04-02 | 江西济民可信集团有限公司 | 环酮并吡啶酮联杂芳环化合物及其制备方法和用途 |
| EP4185587B1 (en) * | 2020-07-22 | 2025-09-10 | JANSSEN Pharmaceutica NV | Compounds useful as factor xia inhibitors |
| JP2024125436A (ja) * | 2021-07-20 | 2024-09-19 | 小野薬品工業株式会社 | イミダゾール化合物の製造方法 |
| US20230097157A1 (en) * | 2021-07-22 | 2023-03-30 | Janssen Pharmaceutica Nv | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors |
| US11958856B2 (en) | 2021-07-22 | 2024-04-16 | Janssen Pharmaceutica Nv | Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors |
| CN113735770B (zh) * | 2021-09-30 | 2023-06-06 | 四川大学 | 一种铑催化的4-苯基噁二唑酮与碳酸亚乙烯酯合成1-氨基异喹啉骨架的方法 |
| CN118974045A (zh) * | 2022-03-21 | 2024-11-15 | 上海济煜医药科技有限公司 | 三并环类化合物制备方法及其中间体 |
| CN116283908A (zh) * | 2023-03-10 | 2023-06-23 | 合肥工业大学 | 一种n-芳香甲基吡啶酮类衍生物及其制备方法与应用 |
| CN118406037B (zh) * | 2024-06-25 | 2025-02-25 | 四川师范大学 | 一种三氮唑类衍生物及其制备方法和用途 |
| CN118894814B (zh) * | 2024-07-15 | 2025-09-12 | 上海康鹏科技股份有限公司 | 1-(2-溴-4-氯苯基)-4-(三氟甲基)-1h-1，2，3-三唑的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0042675A1 (en) | 1980-06-20 | 1981-12-30 | Norton Company | Method of mounting a grinding wheel on a spindle |
| WO1983003968A1 (en) | 1982-05-18 | 1983-11-24 | University Of Florida | Brain-specific drug delivery |
| CA1241120A (en) | 1985-10-01 | 1988-08-23 | Sami A. Aly | Alternate mark inversion (ami) receiver |
| CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| EP0407342A3 (en) | 1989-07-06 | 1991-07-10 | Ciba-Geigy Ag | Pyrimidine derivatives |
| DE4221583A1 (de) * | 1991-11-12 | 1993-05-13 | Bayer Ag | Substituierte biphenylpyridone |
| DE4407488A1 (de) * | 1994-03-07 | 1995-09-14 | Bayer Ag | Verwendung von Biphenyl- und Pyridylmethylpyridonen |
| OA12771A (en) | 2002-02-14 | 2006-07-04 | Pharmacia Corp | Substituted pyridinones as modulators of P38 map kinase. |
| WO2005016911A1 (en) | 2003-08-13 | 2005-02-24 | Takeda Pharmaceutical Company Limited | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006040568A1 (en) | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Quinoxalines as b raf inhibitors |
| CA2588713A1 (en) | 2004-11-24 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors |
| US20070027184A1 (en) | 2005-07-29 | 2007-02-01 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| ES2365815T3 (es) * | 2005-12-14 | 2011-10-11 | Bristol-Myers Squibb Company | Análogos de arilpropionamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor xia. |
| BRPI0620010A2 (pt) | 2005-12-14 | 2011-11-22 | Bristol-Myers Squibb Company | compostos ánalogos de arilpropionamida, arilacrilamida, arilpropinamida, ou arilmetiluréia, processo para sua preparação, composição farmacêutica e uso dos mesmos |
| JP2010510962A (ja) * | 2006-11-24 | 2010-04-08 | 武田薬品工業株式会社 | 複素単環化合物およびその用途 |
| ES2546815T3 (es) | 2006-12-15 | 2015-09-28 | Bristol-Myers Squibb Company | Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa |
| EP2268636A1 (en) | 2007-12-11 | 2011-01-05 | Schering Corporation | Gamma secretase modulators |
| WO2009114677A1 (en) * | 2008-03-13 | 2009-09-17 | Bristol-Myers Squibb Company | Pyridazine derivatives as factor xia inhibitors |
| AU2010211109B2 (en) | 2009-02-06 | 2014-11-27 | Cellzome Limited | Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators |
| MX2013003749A (es) * | 2010-10-07 | 2013-05-09 | Takeda Pharmaceutical | Derivados de 1,4-oxazepano. |
| NO2794597T3 (OSRAM) * | 2011-12-21 | 2018-04-14 |
-
2012
- 2012-12-20 NO NO12813423A patent/NO2794597T3/no unknown
- 2012-12-20 US US14/366,396 patent/US9732085B2/en not_active Expired - Fee Related
- 2012-12-20 EP EP12813423.6A patent/EP2794597B1/en active Active
- 2012-12-20 BR BR112014015669-7A patent/BR112014015669B1/pt not_active IP Right Cessation
- 2012-12-20 CN CN201280070352.3A patent/CN104136431B/zh not_active Expired - Fee Related
- 2012-12-20 JP JP2014548196A patent/JP6137193B2/ja not_active Expired - Fee Related
- 2012-12-20 WO PCT/GB2012/053217 patent/WO2013093484A1/en not_active Ceased
- 2012-12-20 CA CA2859604A patent/CA2859604C/en active Active
- 2012-12-20 DK DK12813423.6T patent/DK2794597T3/en active
- 2012-12-20 AU AU2012356374A patent/AU2012356374B2/en not_active Ceased
- 2012-12-20 ES ES12813423.6T patent/ES2655669T3/es active Active
- 2012-12-20 PT PT128134236T patent/PT2794597T/pt unknown
- 2012-12-20 ES ES17193874T patent/ES2765891T3/es active Active
- 2012-12-20 PL PL12813423T patent/PL2794597T3/pl unknown
- 2012-12-20 HU HUE12813423A patent/HUE036010T2/hu unknown
- 2012-12-20 EP EP17193874.9A patent/EP3290413B9/en not_active Not-in-force
- 2012-12-20 IN IN4676CHN2014 patent/IN2014CN04676A/en unknown
- 2012-12-20 KR KR1020147016952A patent/KR102011534B1/ko not_active Expired - Fee Related
- 2012-12-20 SG SG11201403402VA patent/SG11201403402VA/en unknown
- 2012-12-20 TW TW101148629A patent/TWI613199B/zh not_active IP Right Cessation
- 2012-12-20 RU RU2014129797A patent/RU2630677C2/ru active
- 2012-12-20 MX MX2014007269A patent/MX351471B/es active IP Right Grant
-
2014
- 2014-06-16 PH PH12014501365A patent/PH12014501365B1/en unknown
- 2014-06-16 IL IL233154A patent/IL233154A/en active IP Right Grant
-
2017
- 2017-05-01 JP JP2017091408A patent/JP6447660B2/ja not_active Expired - Fee Related
- 2017-07-07 US US15/644,655 patent/US10717738B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501365B1 (en) | Compounds | |
| US10208034B2 (en) | Quinoline derivative | |
| JP6436205B2 (ja) | キノリン誘導体 | |
| JP6545199B2 (ja) | ３−アミノ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 | |
| RU2733750C2 (ru) | Производные карбоксизамещенных (гетеро)ароматических колец, способ их получения и применение | |
| GB2497806A (en) | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors | |
| WO2019089667A1 (en) | Bridged bicyclic compounds as farnesoid x receptor modulators | |
| JP2004149545A (ja) | Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 | |
| JP7604636B2 (ja) | 新規なジアシルグリセリドｏ－アシルトランスフェラーゼ２阻害剤としてのベンゾイミダゾロン誘導体の製造 | |
| NZ626176B2 (en) | Pyridinone and pyrimidinone derivatives as factor xia inhibitors | |
| HK1198386B (en) | Pyridinone and pyrimidinone derivatives as factor xia inhibitors |